Angiogenesis induced by tumor necrosis factor-α is mediated by α4 integrins

Angiogenesis

Volumn 2, Issue 3, 1998, Pages 265-275

  Vanderslice, Peter ^a   Munsch, Christy L ^a   Rachal, Eugene ^a   Erichsen, David ^a   Sughrue, Kay M ^a   Truong, Ann N ^a   Wygant, James N ^b   McIntyre, Bradley W ^b   Eskin, Suzanne G ^a   Tilton, Ronald G ^a   Polverini, Peter J ^c  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000162365     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009296700991     Document Type: Article

References (45)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1, 27-31.
2. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258, 1798-1801.
3. Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72, 3666-3670.
4. Schweigerer L, Malerstein B, Gospodarowicz D. Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Comm 1987; 143, 997-1004.
5. Frater-Schroder M, Risau W, Hallman R et al. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84, 5277-5281.
6. Leibovich SJ, Polverini PJ, Shepard HM et al. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-α. Nature 1987; 329, 630-632.
7. Fajardo LF, Kwan HH, Kowalski J et al. Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 1992; 140, 539-544.
8. Montrucchio G, Lupia E, Battaglia E et al. Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 1994; 180, 377-382.
9. Pandey A, Shao H, Marks RM et al. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science 1995; 268, 567-569.
10. Yoshida S, Ono M, Shono T et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17, 4015-4023.
11. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct αv integrins. Science 1995; 270, 1500-1502.
12. Osborn L, Hession C, Tizard R et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59, 1203-1211.
13. Bevilacqua MP, Stengelin S, Gimbrone MA, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243, 1160-1165.
14. Koch AE, Halloran MM, Haskell CJ et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376, 517-519.
15. Elices MJ, Osborn L, Takada Y et al. VCAM-1 on activated endothelium interacts with the leukocyte integin VLA-4/fibronectin binding site. Cell 1990; 69, 577-584.
16. Ruegg C, Postigo AA, Sikorski EE et al. Role of integrin α4β7/α4βP in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol 1992; 117, 179-189.
17. Massia SP, Hubbell JA. Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin α4β1. J Biol Chem 1992; 267, 14019-14026.
18. Vanderslice P, Ren K, Revelle JK et al. A cyclic hexapeptide is a potent antagonist of α4 integrins. J Immunol 1997; 158, 1710-1718.
19. B receptors. Am J Physiol 1995; 269, H686-H695.
20. Revelle BM, Scott D, Beck PJ. Single amino acid residues in the E- and P-selectin epidermal growth factor domains can determine carbohydrate binding specificity. J Biol Chem 1996; 271, 16160-16170.
21. Melder RJ, Koenig GC, Witwer BP et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2, 992-997.
22. Robaye R, Mosselmans R, Fiers W, Dumont JE. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells 'in vitro'. Am J Pathol 1991; 138, 447-453.
23. Blystone SD, Lindberg FP, LaFlamme SE, Brown EJ. Integrin αvβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J Cell Biol 1994; 127, 1129-1137.
24. Woodside DG, Teague TK, McIntyre BW. Specific inhibition of T lymphocyte coactivation by triggering integrin β1 reveals convergence of β1, β2, and β7 signaling pathways. J Immunol 1996; 157, 700-706.
25. Diaz-Gonzalez F, Forsyth J, Steiner B, Ginsberg MH. Trans-dominant inhibition of integrin function. Mol Biol Cell 1996; 7, 1939-1951.
26. Porter JC, Hogg N. Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human T cells alters α4β1 and α5β1-mediated function. J Cell Biol 1997; 138, 1437-1447.
27. Imhof BA, Weerasinghe D, Brown EJ et al. Cross talk between αvβ3 and α4β1 integrins regulates lymphocyte migration on vascular cell adhesion molecule 1. Eur J Immunol 1997; 27, 3242-3252.
28. Huhtala P, Humpheries MJ, McCarthy JB et al. Cooperative signaling by α5β1 and α4β1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol 1995; 129, 867-879.
29. van Hinsbergh VWM, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75, 1991-1998.
30. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273, 1551-1554.
31. Lobb RR, Hemler ME. The physiological role of α4 integrins in vivo. J Clin Invest 1994; 94, 1722-1728.
32. Abraham WM, Seilczak MW, Ahmed A et al. α4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 1994; 93, 776-787.
33. Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992; 356, 63-66.
34. Baron JL, Reich E, Visintin I, Janeway CA. The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between α4-integrins and vascular cell adhesion molecule-1. J Clin Invest 1994; 93, 1700-1708.
35. Burkly LC, Jakubowski A, Hattori M. Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin. Diabetes 1994; 43, 529-534.
36. Podolsky DK, Lobb R, King N et al. Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993; 92, 372-380.
37. Isobe M, Suzuki J, Yagita H et al. Immunosuppression to cardiac allografts and soluble antigens by and-VCAM-1 and anti-VLA-4 monoclonal antibodies. J Immunol 1994; 153, 5810-5818.
38. Issekutz AC, Ayer L, Miyasaka M, Issekutz TB. Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease. Immunology 1996; 88, 569-576.
39. Seiffge D. Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. J Rheum 1996; 23, 2086-2091.
40. Scott DL, Willoughby DA, Blake DR. Molecular insights into rheumatoid arthritis. Mol Aspects Med 1991; 12, 341-394.
41. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337, 141-147.
42. Koch AE, Burrows JC, Haines GK et al. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteo arthritic synovial tissues. Lab Invest 1991; 64, 313-320.
43. Morales-Ducret J, Wayner E, Elices MJ et al. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol 1992; 149, 1424-1431.
44. Wellicome SM, Kapahi P, Mason JC et al. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993; 92, 412-418.
45. Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating ICAM-1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating VCAM-1. Arthritis Rheum 1993; 36, 519-527.